Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues-Reference-Cited by-同舟云学术

Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues

Published:2023-11-24 Issue:12 Volume:23 Page:1113-1129
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Salemme Simone¹,Ancidoni Antonio²³,Locuratolo Nicoletta²,Piscopo Paola⁴,Lacorte Eleonora²,Canevelli Marco²⁵,Vanacore Nicola²

Affiliation:

1. Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

2. National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy

3. Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy

4. Department of Neuroscience, Italian National Institute of Health, Rome, Italy

5. Department of Human Neuroscience, “Sapienza” University, Rome, Italy

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2023.2284305

Reference136 articles.

1. Lecanemab in Early Alzheimer’s Disease

2. Donanemab in Early Symptomatic Alzheimer Disease

3. FDA Grants Accelerated Approval For Alzheimer’s Drug. WA (DC): FDA/News & Events/FDA Newsroom/Press Announcements 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug [last accessed 15 Jun 2023]

4. FDA grants accelerated approval for Alzheimer’s disease treatment. WA (DC): FDA/News & Events/FDA Newsroom/Press Announcements 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment [last accessed 15 Jun 2023]

5. Alzheimer's Disease: The Amyloid Cascade Hypothesis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy;Cells;2024-09-12

2. The Profile of the Italian Centers for Cognitive Disorders and Dementia in the Context of New Drugs in Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-09-10

3. EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease;PLOS ONE;2024-08-08

4. Development of a prediction model of conversion to Alzheimer’s disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project;Diagnostic and Prognostic Research;2024-07-25

5. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis;CNS Drugs;2024-03